GLP-1 drugs like Ozempic® and Zepbound® have gained significant attention for treating both diabetes and assisting with weight loss.

Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...

For people who constantly think about what they are going to eat meal to meal, their food noise goes down significantly’ ...

NVO is expanding into rare blood disorders like hemophilia to ease reliance on GLP-1 drugs Ozempic and Wegovy.

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

Compared with DPP-4i, SGLT2i reduced the composite pulmonary endpoint overall, prevented COPD hospitalizations primarily in fit or mildly frail patients, and conferred protection against pneumonia ...

Improving access and affordability could be transformative for public health, given that about 88% of Americans are ...

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

GLP-1RA use necessitated shifting priorities in nutrition and lifestyle modification among patients with obesity, according ...

Multimodal AOMs were associated with the highest preoperative weight loss among patients with high BMI undergoing bariatric surgery.

Dapiglutide, a novel GLP-1/GLP-2 receptor agonist, was associated with body weight reductions of up to 8.3% at 13 weeks for ...